23:50 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) In vitro, cell culture and mouse studies identified a piperazine-based dual MDM2/HDAC6 inhibitor that could help treat NSCLC. Chemical synthesis and in vitro testing of conjugates consisting of analogs of...
05:50 , Jun 2, 2018 |  BioCentury  |  Product Development

Breaking from the herd

Behind the block of clinical studies on PD-1 and PD-L1 inhibitors, researchers are casting aside their herd mentality with a wide net of strategies to solve some of the most pressing problems in oncology, such...
22:25 , Apr 13, 2018 |  BioCentury  |  Emerging Company Profile

Reversing Neuropathy

Regenacy Pharmaceuticals LLC is developing the selective histone deacetylase 6 inhibitor ricolinostat as the first disease-modifying therapy for chemotherapy-induced peripheral neuropathy and diabetic neuropathy. Regenacy was spun out of Acetylon Pharmaceuticals Inc. during its 2016...
16:50 , Feb 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Heart failure Patient sample, rat and mouse studies suggest inhibiting HDAC2 could help treat diastolic dysfunction. In postmortem myofibrils from heart failure patients, diastolic relaxation time was longer than in matched samples from unaffected donors,...
19:50 , Sep 22, 2017 |  BC Week In Review  |  Financial News

Rodin raises $27M in series B

On Sept. 18, Rodin Therapeutics Inc. (Cambridge, Mass.) raised $27 million in a tranched series B round from existing investor Atlas Venture and new investors GV, Hatteras Venture Partners, Remeditex Ventures and Third Point Ventures....
19:58 , Sep 21, 2017 |  BC Innovations  |  Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
11:05 , Sep 18, 2017 |  BC Extra  |  Financial News

Rodin raises $27M series B

Rodin Therapeutics Inc. (Cambridge, Mass.) raised $27 million in a tranched series B round from existing investor Atlas Venture and new investors GV, Hatteras Venture Partners, Remeditex Ventures and Third Point Ventures. Details regarding the...
16:22 , Aug 31, 2017 |  BC Innovations  |  Translation in Brief

Extinguishing aversion

Last month in the Journal of Neuroscience, a team from the Chinese Academy of Sciences showed activating RAC1 could help treat opioid addiction by extinguishing the aversive memories of withdrawal that cause relapse in some...
20:56 , Aug 17, 2017 |  BC Innovations  |  Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
18:03 , Feb 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Nerve damage Studies in mice suggest inhibiting HDAC2 could help treat peripheral nerve damage. In a mouse model of sciatic nerve injury, Schwann cell-specific knockout of HDAC2 increased axonal regrowth and sprouting compared with normal...